Clinical trial adaptation by matching evidence in complementary patient sub-groups of auxiliary blinding questionnaire responses by Arandjelović, Ognjen
  
 
 
 
Arandjelović, Ognjen 2015, Clinical trial adaptation by matching evidence in complementary patient sub-
groups of auxiliary blinding questionnaire responses, PLoS one, vol. 10, no. 7, pp. 1-24. 
 
DOI: 10.1371/journal.pone.0131524 
 
 
This is the published version. 
 
©2015, The Authors 
 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30081827 
RESEARCH ARTICLE
Clinical Trial Adaptation by Matching
Evidence in Complementary Patient Sub-
groups of Auxiliary Blinding Questionnaire
Responses
Ognjen Arandjelović*
Centre for Pattern Recognition and Data Analytics, School of Information Technology, Deakin University,
Geelong, Victoria, Australia
* ognjen.arandjelovic@gmail.com
Abstract
Clinical trial adaptation refers to any adjustment of the trial protocol after the onset of the
trial. Such adjustment may take on various forms, including the change in the dose of
administered medicines, the frequency of administering an intervention, the number of trial
participants, or the duration of the trial, to name just some possibilities. The main goal is to
make the process of introducing new medical interventions to patients more efficient, either
by reducing the cost or the time associated with evaluating their safety and efficacy. The
principal challenge, which is an outstanding research problem, is to be found in the question
of how adaptation should be performed so as to minimize the chance of distorting the out-
come of the trial. In this paper we propose a novel method for achieving this. Unlike most of
the previously published work, our approach focuses on trial adaptation by sample size
adjustment i.e. by reducing the number of trial participants in a statistically informed manner.
We adopt a stratification framework recently proposed for the analysis of trial outcomes in
the presence of imperfect blinding and based on the administration of a generic auxiliary
questionnaire that allows the participants to express their belief concerning the assigned
intervention (treatment or control). We show that this data, together with the primary mea-
sured variables, can be used to make the probabilistically optimal choice of the particular
sub-group a participant should be removed from if trial size reduction is desired. Extensive
experiments on a series of simulated trials are used to illustrate the effectiveness of our
method.
Introduction
Robust evaluation is a crucial component in the process of introducing new medical interven-
tions. Amongst others, these include newly developed medications, novel means of administer-
ing known treatments, new screening procedures, diagnostic methodologies, physio-
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therapeutical manipulations, and many others. Such evaluations usually take on the form of a
controlled clinical trial (or a series thereof), the framework widely accepted as best suited for a
rigourous statistical analysis of the effects of interest [1–3] (for a related discussion and critique
also see [4]). Driven both by legislating bodies, as well as the scientific community and the pub-
lic, the standards that the assessment of novel interventions are expected to meet continue to
rise. Generally, this necessitates trials which employ larger sample sizes and which perform
assessment over longer periods of time. A series of practical challenges emerge as a conse-
quence. Increasing the number of individuals in a trial can be difficult because some trials
necessitate that participants meet specific criteria; volunteers are also less likely to commit to
participation over extended periods of time. The financial impact is another major issue—both
the increase in the duration of a trial and the number of participants result in additional cost to
an already expensive process. In response to these challenges, the use of adaptive trials has
emerged as a potential solution [5–9].
The key idea underlying the concept of an adaptive trial design is that instead of fixing the
parameters of a trial before its onset, greater efficiency can be achieved by adjusting them as
the trial progresses [10]. For example, the trial sample size (e.g. the number of participants in a
trial), treatment dose or frequency, or the duration of the trial may be increased or decreased
depending on the accumulated evidence [11–13].
Proposed method overview
The method for trial adaptation we describe in this paper extends the analysis presented in [14]
which has been greatly influenced by recent work on the analysis of imperfectly blinded clinical
trials [15, 16]. Its key contribution was to introduce the idea of trial outcome analysis by patient
sub-groups which comprise trial participants matched by the administered intervention (treat-
ment or control) and their responses to an auxiliary questionnaire in which the participants are
asked to express their belief regarding their assignment intervention in the closed-form (see
Auxiliary data collection for a summary of the adopted sub-group stratification method and
the original paper [16] for full detail). This framework was shown to be suitable for robust
inference in the presence of “unblinding” in a trial [16, 17]. The method proposed in the pres-
ent paper emerges from the realization that the same framework can be used for trial adapta-
tion by providing information which can be used to make a statistically informed selection of
the trial participants which can be dropped from the trial before its completion, without signifi-
cantly affecting the trial outcome. Thus, the proposed approach falls under the category of trial
adaptations by “amending sample size”, in contrast to “dose finding” or “response adapting”
methods which dominate previous work [13].
In [16] it was shown that the analysis of a trial’s outcome should be performed by aggregat-
ing evidence provided by matched participant sub-groups, where two sub-groups are matched
if they contain participants who were administered different interventions but nonetheless had
the same responses in the auxiliary questionnaire. Therefore, our idea advanced here is that an
informed trial sample size reduction can be made by computing which matched sub-group
pair’s contribution of useful information is affected the least with the removal of a certain num-
ber of participants from one of its groups.
Contrast with previous work. Before introducing the proposed method in detail, it is
worthwhile emphasizing two fundamental aspects in which it differs from the methods previ-
ously described in the literature. The first difference concerns the nature of the statistical
framework which underlies our approach. While the use of Bayesian techniques has become
increasingly common in medical statistics [18–22], and perhaps particularly so in the context
of clinical trial design and analysis [18, 23–28], with few notable exceptions [29] the existing
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work on trial adaptation by sample size adjustment adopts the frequentist paradigm [30–32].
These methods follow the following general pattern: a particular null hypothesis is formulated
which is then rejected or accepted using a suitable statistic and the desired confidence require-
ment (a good review is provided by Jennison and Turnbull [33]). In contrast, the method
described in this paper is thoroughly Bayesian in nature.
The second major conceptual novelty of the proposed method lies in the question it seeks to
answer. Previous work on trial adaptation by sample size adjustment addresses the question of
whether the sample size can be reduced while maintaining a certain level of statistical signifi-
cance of the trial’s outcome. In contrast, the present work is the first to ask a complementary
question of which particular individuals in the sample should be removed from the trial once
the decision of sample size reduction has been made. Thus, the proposed method should not
be seen as an alternative to the any of the previously proposed methods but rather as a comple-
mentary element of the same framework.
Auxiliary data collection
The type of auxiliary data collection we utilize in this work was originally proposed for the
assessment of blinding in clinical trials [34]. Since then it has been adopted for the same pur-
pose in a number of subsequent works [16, 35–37] (also see [38] for related commentary).
With the exception of [16], in all previous work the questionnaire is employed after the trial
has ended (for discussions on the timing of the questionnaire see [16, 39, 40]). The question-
naire allows the trial participants to express their belief on the nature of the intervention they
have been administered (control or treatment) using a fixed number of choices. The most com-
monly used, coarse-grained questionnaire admits the following three choices:
Choice 1: the patient believes that he/she was administered the control intervention (i.e. control
group membership),
Choice 2: the patient believes that he/she was administered the treatment intervention (i.e.
treatment group membership), and
Choice 3: the patient is undecided about the nature of the treatment he/she was administered
(the “don’t know” response).
Extensions of this scheme which attempt to harness more detailed information have also been
used, for example allowing the participants to quantify the conviction of their belief as “weak”
or “strong”. In that case, the questionnaire would offer five choices:
Choice 1: the patient strongly believes that he/she was administered the control intervention,
Choice 2: the patient weakly believes that he/she was administered the control intervention,
Choice 3: the patient is undecided about the nature of the treatment he/she was administered,
Choice 4: the patient weakly believes that he/she was administered the treatment intervention,
and
Choice 5: the patient strongly believes that he/she was administered the treatment intervention.
More granular auxiliary data choices have the potential of providing a more accurate picture of
the extent of blinding. However, depending on the statistical model used, this advantage may
come at the cost of reduced statistical significance for each of the response sub-groups. The evi-
dence on the capacity of a human’s working memory [41] suggests that the number of compar-
isons a typical person can distinguish at any one time is approximately 7±2, which leads to the
conclusion that it is best to limit the number of choices to fewer than ten.
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Matching sub-groups outcome model
In the general case, the effectiveness of a particular intervention in a trial participant depends
on the inherent effects of the intervention, as well as the participant’s expectations (conscious
or not). Thus, as in [16], in the interpretation of trial results, we separately consider each popu-
lation of participants which share the same combination of the type of intervention and the
expressed belief regarding this group assignment. For example, when a 3-tier questionnaire is
used in a trial comparing the administration of the treatment of interest and control, we recog-
nize 3×2 = 6 auxiliary data sub-groups:
Sub-group 1: participants of the control group who believe they were assigned to the control
group (sub-group GC−),
Sub-group 2: participants of the control group who are unsure of their group assignment (sub-
group GC0),
Sub-group 3: participants of the control group who believe they were assigned to the treatment
group (sub-group GC+),
Sub-group 4: participants of the treatment group who believe they were assigned to the control
group (sub-group GT−),
Sub-group 5: participants of the treatment group who are unsure of their group assignment
(sub-group GT0), and
Sub-group 6: participants of the treatment group who believe they were assigned to the treat-
ment group (sub-group GT+).
This is illustrated conceptually in Fig 1. In the general case, for an N-tier questionnaire andM
different intervention types, we can distinguish between N×M distinct sub-groups of
participants.
The key idea underlying the method proposed in [16] is that because the outcome of an
intervention depends on both the inherent effects of the intervention and the participants’
expectations, the effectiveness should be inferred in a like-for-like fashion. In other words, the
response observed in, say, the sub-group of participants assigned to the control group whose
feedback professes belief in the control group assignment should be compared with the
response of only the sub-group of the treatment group who equally professed belief in the
Fig 1. Adopted statistical model for a three-tier feedback questionnaire (conceptual illustration)—the probability densities of the measured trial
outcome across the three control (solid lines) and treatment sub-groups (dotted lines).Diagram reproduced with permission.
doi:10.1371/journal.pone.0131524.g001
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control group assignment. Similarly, the “don’t know” sub-groups should be compared only
with each other, as should the sub-groups corresponding to the belief in the treatment assign-
ment. Ideas similar in spirit were expressed by Berger in the consideration of the related prob-
lem of so-called selection bias and specifically the Berger-Exner test [42].
Sub-group selection
The primary aim of the statistical framework described in [16] is to facilitate an analysis of trial
data robust to the presence of partial or full unblinding of patients, or indeed patient precon-
ceptions which too may affect the measured outcomes. Herein we propose to exploit and
extend this framework to guide the choice of which patients are removed from the trial after its
onset, in a manner which minimizes the loss of statistical significance of the ultimate
outcomes.
At the onset of the trial, the trial should be randomized according to the current best clinical
practice; this problem is comprehensively covered in the influential work by Berger [42]. If a
reduction in the number of trial participants was attempted at this stage, by the very definition
of a properly randomized trial, statistically speaking there is no reason to prefer the removal of
any particular subject (or indeed a set of subjects) over another. Instead, any trial size adapta-
tion must be performed at a later stage after some meaningful differentiation between subjects
takes place [43–45].
The most obvious measurable differentiation that takes place between patients as the trial
progresses is that of the outcomes of primary interest in the trial (the “response”). This differ-
entiation may allow for a statistically informed choice to be made about which trial participants
can be dropped from the trial in a manner which minimizes the expected distortion of the ulti-
mate findings. For example, this can be done by seeking to preserve the distribution of mea-
sured outcomes within a group (treatment or control) but with the constraint of a smaller
number of participants; indeed, our approach partially exploits this idea as will be explained in
detail shortly. However, our key contribution lies in a more innovative approach, which
exploits additional, yet readily collected discriminative information. The proposed approach
not only minimizes the effect of smaller participant groups but also ensures that no uninten-
tional bias is injected due to imperfect blinding. Recall that the problem of inference robust to
imperfect blinding should always be considered—as stated earlier, blinding can only be
attempted with respect to those variables of the trial which have been identified as revealing of
the administered treatment, and even for the explicitly identified variables it is fundamentally
impossible to ensure that absolute blinding is achieved.
Our idea is to administer an auxiliary questionnaire of the form described in [34, 35] (which
is normally administered after the trial in the work on blinding assessment) every time an
adaptation of the trial group size (i.e. reduction thereof) is sought. Just like in [16], this leads to
the differentiation of each group of participants (control or treatment) into sub-groups, based
on their belief regarding their group assignment. In general, this means that even if no partici-
pants are removed from the trial, a participant may change his/her sub-group membership sta-
tus. This is illustrated conceptually in Fig 2. The first time an auxiliary questionnaire is
administered (top-most plot), most of the treatment group participants are still unsure of their
assignment (solid blue line); a smaller number of participants have correctly guessed (or
inferred) their assignment (bold blue line); lastly, an even smaller number holds the incorrect
belief that they are in fact members of the control group (dotted blue line). All of the sub-
groups show a spread of responses to the treatment, such as may be expected due to various
personal variations of their members. At the time of the second snapshot (plot in the middle),
at the next instance when auxiliary data is collected, the proportions of participants in each
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sub-group has changed, as do the associated treatment response statistics. A similar observa-
tion can be made with respect to the third and the last snapshot pictured in the figure (bottom-
most plot). This sort of a development would not be unexpected—if the treatment is effective,
as the trial progresses there will be an increase in the number of treatment group participants
who observe and correctly interpret these changes (note that this also means that there will be
an associated increase in the number of participants who may exhibit an additional positive
effect from the fortunate realization that they are receiving the studied treatment intervention,
rather than the control intervention). That being said, it should be emphasized that no
Fig 2. A conceptual illustration on a hypothetical example of the phenomenon whereby trial participants change their sub-groupmembership
(recall that each sub-group is defined by its members’ intervention assignment and auxiliary questionnaire responses). This is quite likely to occur
when the effects of the treatment are very readily apparent but various other mechanisms can act so as to cause a non-zero and changing sub-group flux.
doi:10.1371/journal.pone.0131524.g002
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assumption on the statistics of sub-group memberships or their relative sizes is made in the
proposed method. The example in Fig 2 is merely used for illustrative purposes.
The question is: how does this differentiation of patients by auxiliary data sub-groups help
us make a statistically robust choice of which participants in the trial should be preferentially
dropped if a reduction in the trial size is sought? To answer this question, recall the main prem-
ise of [16]:
“The key idea [. . .] is that it is meaningful to compare only the corresponding treatment
and control participant sub-groups, that is, sub-groups matched by their auxiliary
responses.”
Each sub-group comparison contributes information used to infer the probability density of
the differential effects of the treatment. We can then reformulate the original question as: from
which matching sub-group pair should participants be preferentially dismissed from further
consideration so as to best preserve the information contribution from all sub-groups?
Consider how the information on the differential effects between a single pair of matching
sub-groups is inferred. In its general form, we can estimate some distance between the distribu-
tions of the two sub-groups using a Bayesian approach. Indeed, Bayesian analysis based meth-
ods have in recent years been continually gaining acceptance across the clinical community
[44]. In brief, the key idea is to “integrate out” the unknown latent parameters of the two distri-
butions. Expressed formally:
r ¼
Z
Yc
Z
Yt
rðpcðx;YcÞ; ptðx;YtÞÞ|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
Distance between distributions
for specific parameter values
 pðYcjDcÞ pðYtjDtÞ|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
Probability of parameters
conditioned on observations
 pðYcÞ pðYtÞ|ﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄ}
Parameter priors
 dYt dYc ð1Þ
where Θc and Θt are the sets of variables parameterizing the two corresponding distributions
pc(x;Θc) and pt(x;Θt), p(Θc) and p(Θt) the parameter priors, ρ(pc(x;Θc),pt(x;Θt)) a particular dis-
tance function (e.g. the Kullback-Leibler divergence [46], Bhattacharyya [47] or Hellinger dis-
tances [48], or indeed the posterior of the difference of means used in [16]), and Dc and Dt the
measured trial outcomes (such as the amount of fat loss in a fat loss trial, the reduction in
blood plasma LDL in a statin trial etc).
Note that by changing (reducing) the number of participants in one of the groups, the only
affected term on the right hand side of Eq (1) is one of the likelihood terms, p(ΘcjDc) or p
(ΘtjDt). Seen another way, a change in the number of participants in the trial changes the
weighting of the product of the distance term ρ(pc(x;Θc),pt(x;Θt)) and the priors p(Θc) p(Θt).
Our idea is then to choose to remove a trial participant from that sub-group which produces
the smallest change in the estimate ρ. However, it is not clear how this may be achieved, since
it is the size of the set Dc that is changing (so, for example, treating Dc and Dt as vectors and f as
a function of vectors would not achieve the desired aim). Examining the sensitivity of ρ with
the removal of each datum (i.e. trial participant) from Dc and Dt is also unsatisfactory since the
problem does not lend itself to a greedy strategy: the optimal choice of which nrem trial partici-
pants to drop from the trial cannot be made by making nrem optimal choices of which one par-
ticipant to drop. An approach following this direction but attempting to examine all possible
sets of size nrem would encounter computational tractability obstacles since this problem is NP-
complete. The alternative which we propose is to consider and compare the magnitudes of par-
tial derivatives of ρ with respect to the sizes of data sets Dc and Dt, but with an important con-
straint—the derivatives are taken of the expected functional form of ρ over different members
Clinical Trial Adaptation by Matching Evidence in Patient Sub-Groups
PLOS ONE | DOI:10.1371/journal.pone.0131524 July 10, 2015 7 / 24
of Dc and Dt. Formalizing this, we compute:
E
@r
@nc
 
Dc
and E
@r
@nt
 
Dt
; ð2Þ
where E[ρ]Dc and E[ρ]Dt are respectively the expected values of ρ across the space of possi-
ble observations in Dc and Dt (each with a uniform prior, as before). Thus E[ρ]Dc and E[ρ]Dt
are functions of two scalars, the sizes nc and nt of sets Dc and Dt i.e. the numbers of members of
the corresponding sub-groups.
The proposed solution is not only theoretically justified but it also lends itself to simple and
efficient implementation. Since the expected values E[ρ]Dc and E[ρ
]Dt are evaluated over sets
Dc and Dt, in Eq (1) the only term affected is p(ΘcjDc) p(ΘtjDt), so the solution is readily
obtained as a closed form expression. Equally, the integration is readily performed using one of
the standard Markov chain Monte Carlo integration methods [49].
Application example
In order to illustrate how the described idea could be applied in practice, we now consider one
specific example of the distance function discussed in the previous section and show how the
mathematical results needed to implement the proposed methodology can be derived or esti-
mated. Readers who are not interested in full technical detail of this nature can skip this section
and proceed to Note on practical application without loss in continuity.
Let the trial observation data in two matching sub-groups be drawn from the random vari-
ables Xc and Xt, which are appropriately modelled using log-normal distributions [50]:
Xt 
1
x st
exp  ln x mt
2s2t
 
ð3Þ
and
Xc 
1
x sc
exp  ln x mc
2s2c
 
ð4Þ
The next step is to choose an appropriate distance function ρ in Eq (1). In practice, this choice
would be governed by the goals of the study. Herein, for illustrative purposes we choose ρ to be
the probability that a patient will do better when the treatment rather than the control inter-
vention is administered:
rðptðx;YtÞ; pcðy;YcÞÞ ¼
Z 1
0
Z x
0
ptðx;YtÞ pcðy;YcÞ dy dx
where Θc = (mc,σc) and Θt = (mt,σt) are the mean and standard deviation parameters specifying
the corresponding log-normal distributions.
r /Z 1
0
Z 1
1
Z 1
0
Z 1
1
Z 1
0
Z x
0
n
ptðxjmt; stÞ pðmt;stÞ dx dmt dst  pcðyjmc; scÞ pðmc;scÞ dy dmc dsc
o
ð5Þ
Making the usual substitution whereby ex is substituted for x (and similarly ey for y), which
normalizes the log-normal distribution, and assuming uninformed priors onmc,mt, σc, and σt
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(just as in [16]) leads to the following expression
r /
Z1
0
Z1
1
Z1
0
Z1
1
Z1
0
Zx
0
s1t e
ðxmt Þ
2
2s2
t sNt e

Pnt
i¼1 ðx
ðtÞ
i
mt Þ2
2s2
t dx dmtdst
 s1c e
ðxmcÞ
2
2s2c sNc e

Pnc
i¼1 ðx
ðcÞ
i
mcÞ2
2s2c dy dmcdsc ð6Þ
¼
Z1
0
Zx
0
ItðxÞIcðyÞdy dx ¼
Z1
0
ItðxÞ
Zx
0
IcðyÞdy dx ð7Þ
where each of the integrals It(x) and Ic(y) has the form:
I ¼
Z 1
0
Z 1
1
1
s
exp ðx mÞ
2
2s2
 
 1
sn
exp 
Pn
i¼1 ðxi mÞ2
2s2
 
dm ds; ð8Þ
{xi} and n stand for either x
ðcÞ
i
n o
and nc or x
ðtÞ
i
n o
and nt, and x
ðcÞ
i
n o
(i = 1. . .nc) and x
ðtÞ
i
n o
(i = 1. . .nt) are exponentially transformed measured trial variables. This integral can be evalu-
ated by combining the two exponential terms and completing the square of the numerator of
the exponent as in [16] so that:
ðx mÞ2 þ
Xn
i¼1
ðxi mÞ2  ðamþ bÞ2 þ c; ð9Þ
which leads to the following simpliﬁcation of Eq (7):
I /
Z1
0
1
snþ2
exp  c
2s2
n o
s ds ð10Þ
¼
Z1
0
1
snþ1
exp  c
2s2
n o
ds; ð11Þ
where the value of the only non-constant term, c, is:
c ¼ x2 þ
Xn
i¼1
xi
2  ðx þ
Pn
i¼1 xiÞ2
nþ 1 ð12Þ
¼ ðnþ 1Þðx
2 þPni¼1 xi2Þ  ðx þPni¼1 xiÞ2
nþ 1 : ð13Þ
Observing that the form of the integrand in Eq (11) matches that of the inverse gamma dis-
tribution:
Gammaðz; a; bÞ ¼ b
a
GðaÞ z
a1expfb=zg: ð14Þ
where Γ(α) is the value of the gamma function at α. The variable z and the two parameters of
the distribution, α and β, can be matched with the terms in Eq (11) and the density integrated
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out, leaving the integral proportional to a single non-constant term:
I / cn12 : ð15Þ
Notice that the form of this result is very similar to that obtained in [16].
Remembering that the functional form of c is different for the control and the trial groups
(since it is dependent on xi which stands for either x
ðcÞ
i or x
ðtÞ
i ), and substituting the result from
Eq (15) back into Eq (7) gives the following expression for the distance function:
r ¼
Z1
0
Zx
0
ptðxÞpcðyÞdy dx ð16Þ
/
Z1
0
Zx
0
c
nt12
t c
nc12
c dy dx ð17Þ
¼
Z1
0
c
nt12
t
Zx
0
c
nc1
2
c dy dx ð18Þ
Our goal now is to evaluate Sc(ρ) and St(ρ), the sensitivities of the distance function to the
change in the size of respectively the control and the treatment groups. Without loss of general-
ity, let us consider St(ρ)—the symmetry of the expression in Eq (18) makes it trivial to apply
the same process to the computation of St(ρ). From Eq (18):
StðrÞ /
Z1
1
Zx
1
S½ItðxÞIcðyÞdy dx ð19Þ
To evaluate S[It(x)] we will employ the standard chain rule and perform differentiation with
respect to nt when the corresponding term is a function of the number of treatment partici-
pants but not any xðtÞi . On the other hand, as proposed in Sub-group selection, to handle those
terms which do depend on xðtÞi (through ct), we will use the expected value of the change in the
term, averaged over all possible xðtÞi that a unitary decrease in nt can be achieved. Applying this
idea on the expression in Eq (8) leads to the following expansion:
S½ItðxÞ ¼ 
Z1
0
Z1
1
1
s
exp ðx mÞ
2
2s2
 
 lns
sn
exp 
Pn
i¼1 ðxi mÞ2
2s2
 
þ 1
sn
exp 
Pn
i¼1 ðxi mÞ2
2s2
 Pn
i¼1 ðxi mÞ2
2s2n2
 
dm ds ð20Þ
noting that we used the standard result:
d
dn
1
sn
¼  lns
sn
ð21Þ
without including its derivation with intermediary steps shown explicitly. The resulting
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expression can be further rearranged, yielding the following, more concise expression:
S½ItðxÞ ¼ 
Z1
0
Z1
1
lns
sn
exp ðx mÞ
2
2s2
 
 exp 
Pn
i¼1 ðxi mÞ2
2s2
 
dm ds ð22Þ

Z1
0
Z1
1
1
snþ3n2
exp ðx mÞ
2
2s2
 
 exp 
Pn
i¼1 ðxi mÞ2
2s2
 Xn
i¼1
ðxi mÞ2dm ds: ð23Þ
Full double integration of the integrands in Eq (23) is difficult to perform analytically. How-
ever, one level of integration—with respect tom—is readily achieved. Note that the first term,
as a function ofm, has the same form as the integral in Eq (8) which we already evaluated. The
same procedure which uses the completion of the square in the exponential term can be
applied here as well (note that unlike in Eq (8) here it is important to keep track of the multipli-
cative constants as these will be different for the second term in Eq (23)). The integrand in the
second term can be expressed in the form/ (z−λ)2 exp−z2 dz. This integration is also readily
performed using the standard results:
Z1
1
1ﬃﬃﬃﬃﬃ
2p
p z2 exp z
2
2
dz ¼ 1 ð24Þ
and
Z1
1
1ﬃﬃﬃﬃﬃ
2p
p exp z
2
2
dz ¼ 1; ð25Þ
and by noting that the integrand is an odd function
Z1
1
1ﬃﬃﬃﬃﬃ
2p
p z exp z
2
2
dz ¼ 0 ð26Þ
A straightforward application of these results to Eq (23) leads to the following expression for
the sensitivity S[It(x)] of the integral It to changes in the size of the corresponding sub-group
(the treatment sub-group in a matching pair):
S½ItðxÞ ¼ 
Z1
0
lns
snþ1
s
a
ﬃﬃﬃﬃﬃ
2p
p
exp  c
2s2
n o
ds
Z1
0
exp  c
2s2
 	
2snþ3n2
n
s
a

 3
þ
ﬃﬃﬃﬃﬃ
2p
p s
a
Xn
i¼1
xi
" #
ds ð27Þ
This result, together with the expression in Eq (15), can be substituted into Eq (19) and the
remaining integration performed numerically.
Note on practical application
As demonstrated in the preceding section, it is worth observing that none of the calculations
involved make any strong assumptions on the nature of the phenomenon studied i.e. the nature
of the outcome data. There are only two elements of the described framework which are subject
to change depending on the trial. These are the distance function ρ and the form of the likeli-
hood terms p(ΘcjDc) and p(ΘtjDt), see Eq (1). In practice, all of these terms are confined to a
small number of reasonable options, which means that all of the derivations described in some
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detail in the previous section can be performed a priori, with only the final numerical computa-
tions (which are not computationally demanding) performed “on the fly”. Consequently, while
the implementation of the proposed approach clearly requires expertise in mathematics and
computation, no mathematical expertise or thorough understanding of the details of the algo-
rithm need to be expected from the user (e.g. a clinician or a biostatistician). The user would
merely need to select one of a number of possible outcomes of interest (e.g. “effect greater
than”) and set the value of the relevant parameter according to the aims of the study (e.g.
“effect greater than 0.1”), and be automatically presented with the best sample selection and
the corresponding posterior distributions quantifying the uncertainty associated with the resul-
tant outcome. This will be illustrated shortly on simulated examples in Evaluation and
analysis.
From target sub-groups to specific participants
Adopting the framework proposed in [16] whereby the analysis of a trial takes into account
sub-groups of trial participants, which emerge from grouping participants according to their
assigned intervention and auxiliary data, thus far we focused on the problem of choosing the
sub-group from which participants should be preferentially removed if a reduction in trial size
is sought. The other question which needs to be considered is how specific sub-group members
are to be chosen, once the target sub-group is identified. Fortunately, the proposed framework
makes this a simple task. Recall that the observed trial data within each sub-group is assumed
to comprise an identically and independently distributed sample from the underlying distribu-
tion, i.e. xðcÞi  Xc (or indeed xðtÞi  Xt). This means that it is sufﬁcient to randomly sample the
set of target sub-group members to select those which can be removed.
The simplicity of the selection process that our approach allows has an additional welcome
consequence. Recall that in the proposed method the choice of the target sub-group is made by
comparing differentials in Eq (2). It is important to observe that their values are computed for
the initial values of nc and nt. Thus, as the number of participants in either of the sub-groups is
changed, so do the values of the differentials, and thus possibly the optimal sub-group choice.
This is why the removal of participants should proceed sequentially as summarized in Fig 3.
Evaluation and Analysis
The primary novelty introduced in this paper is of a methodological nature. In the previous
section we explained in detail the mathematical process involved in applying the proposed
methodology in practice. Pertinent results were derived for a specific distance function used to
Fig 3. A ‘high-level’ summary of the key steps in the proposedmethod.
doi:10.1371/journal.pone.0131524.g003
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quantify the difference in the outcomes between the control and treatment groups in a trial.
The choice of the distance function—which would in practice be made by the clinicians to suit
the aims of a specific trial—governs the relative loss of information when participants are
removed from a specific sub-group, and consequently dictates the choice of the optimal sub-
group from which the removal should be performed if the overall trial sample size needs to be
reduced.
In this section we apply the derived results on experimental data, and evaluate and discuss
the performance of the proposed methodology. We adopt the evaluation protocol standard in
the domain of adaptive trials research, and obtain data using a simulated experiment.
Experimental setup
We simulated a trial involving 180 individuals, half of which were assigned to the control and
the other half to the treatment group. For each individual we maintain a variable which
describes that person’s belief regarding his/her group assignment. Thus, for the control group
we have nc beliefs b
ðcÞ
i
n o
(i = 1. . .nc) and similarly for the treatment group nt beliefs b
ðtÞ
i
n o
(i = 1. . .nt). Belief is expressed by a real number, 8i:bðcÞi ; bðtÞi 2 ð1;þ1Þ, with 0 indicating
true undecidedness. Negative beliefs express a preference towards the belief in control group
assignment, and positive towards the belief in treatment group assignment. The greater the
absolute value of a belief variable is, the greater is the person’s conviction. We employ a three-
tier questionnaire. To simulate a participant’s response, we map the corresponding belief to
one of the three possible questionnaire responses according to the following thresholding rule:
b < 1 ! Belief incontrolgroupassignment ð28Þ
1  b  1 ! Uncertainð“don’t know”Þ ð29Þ
1 < b! Belief intreatmentgroupassignment ð30Þ
The starting beliefs of participants, i.e. their beliefs before the onset of the trial, are initialized as
follows:
bðcÞi ¼ bðtÞi
1 for i ¼ 1 . . . 8
0 for i ¼ 9 . . . 81
1 for i ¼ 82 . . . 90
ð31Þ
8><
>:
Put in informal terms, this initialization reﬂects the conservative belief of most individuals, and
the tendency of a smaller number of individuals to exhibit either “pessimistic” or “optimistic”
expectations. Also, notice that the same distribution was used both for the control and the
treatment groups, reﬂecting a well performed randomization in the group assignment process.
Effect accumulation. As the trial progresses the effects of the treatment accumulate. These
are modelled as positive i.e. the treatment is modelled as successful in the sense that on average
it produces a superior outcome in comparison with the control intervention. We model this
using a stochastic process which captures the variability in participants’ responses to the same
treatment. Specifically, at the discrete time step k+1 (the onset of the trial corresponding to
k = 0), the effect of the i-th treatment group participant at the preceding time step k, eðcÞi (k), is
updated in the following manner:
eðtÞi ðkþ 1Þ ¼ eðtÞi ðkÞ þ wðtÞi ðkþ 1Þ  exp 
kþ 1
10
 
ð32Þ
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where wðtÞi ðkþ 1Þ is drawn from a normal distribution:
Wt  N ð0:02; 0:05Þ: ð33Þ
Notice that this progression has a ‘ground truth’ asymptote at:
lim
k!1
E½eðtÞi ðkÞ ¼ eðtÞi ð0Þ þ 0:02
exp  1
10
 	
1 exp  1
10
 	 	 eðtÞi ð0Þ þ 0:19 ð34Þ
Similarly, for the control group participants:
eðcÞi ðkþ 1Þ ¼ eðcÞi ðkÞ þ wðcÞi ðkþ 1Þ  exp 
kþ 1
10
 
ð35Þ
where wðcÞi ðkþ 1Þ is drawn from a normal distribution:
Wc  N ð0:00; 0:05Þ ð36Þ
By deﬁnition, at the onset of the trial there is no effect of the treatment; thus:
8:i ¼ 1 . . . nt:eðtÞi ð0Þ ¼ 0 ð37Þ
8:i ¼ 1 . . . nc:eðcÞi ð0Þ ¼ 0 ð38Þ
Belief refinement. As the effects of the respective interventions are exhibited, the trial par-
ticipants have increasing amounts of evidence available guiding them towards forming the cor-
rect belief regarding their group assignment. In our experiment this process is also modelled
using a stochastic process which is dependent on the magnitude of the effect that an interven-
tion has in a particular participant, as well as uncertainty and differences in people’s inference
from observations. At the discrete time step k+1, the belief of the i-th control group participant
previous at the time step k, bðcÞi (k), is updated using the following update equation:
bðcÞi ðkþ 1Þ ¼ bðcÞi ðkÞ þ  eðcÞi ðkþ 1Þ þ oðcÞi ðkþ 1Þ ð39Þ
where oðcÞi ðkþ 1Þ is drawn from a normal distribution:
O  N ð0:00; 0:005Þ: ð40Þ
The model parameter ϕ captures the ease with which an improvement (or equivalently, a dete-
rioration) in the outcome is observed by a patient. For example in a trial where the outcome of
interest is, say, muscular strength or mobility [51], observability is high. In contrast, in a trial
which examines the effects of different interventions on, say, bone mineral density [52], the
patient is entirely or virtually entirely unable to gauge relevant changes. As expected from the
theory presented in the previous sections and as we shall demonstrate empirically, this aspect
of a clinical trial under consideration has important consequences on the beneﬁt of sample
selection proposed in this work. This is investigated in detail in the next section.
The changes in the beliefs of the treatment group are modelled in the identical manner to
those of control group participants:
bðtÞi ðkþ 1Þ ¼ bðtÞi ðkÞ þ  eðtÞi ðkþ 1Þ þ oðtÞi ðkþ 1Þ ð41Þ
Clinical Trial Adaptation by Matching Evidence in Patient Sub-Groups
PLOS ONE | DOI:10.1371/journal.pone.0131524 July 10, 2015 14 / 24
where oðtÞi ðkþ 1Þ is again drawn from a normal distribution:
Oc  N ð0:00; 0:005Þ ð42Þ
Experiment 1: Baseline performance
Using the model for generating longitudinal patient data described in Experimental setup, in
this experiment we compared the proposed method with random sample selection in the con-
text of a single sample size reduction step. In particular we simulated the reduction in the total
number of participants of n = 70 (i.e. approximately 39% of the total cohort size of 180) after
k = 50 time steps; please see Eqs (32)–(41). Following the removal time step, data accrual of the
selected participants was discontinued. Note that in this experiment the data collected from the
removed patients up to the time step k = 50 was used in the final outcome analysis. The trial
was simulated for the total number of kmax = 100 time steps after which the outcomes were
used to infer the differential effects of the two simulated interventions. The final outcomes
both in the case of the proposed method and random selection were analysed using the Bayes-
ian method proposed in [16]. The observability parameter in this experiment was set to ϕ =
0.01, please see Eq (39). Finally, to facilitate robust analysis, the experiment was repeated 100
times, resulting in different patient states, effects of the two interventions (treatment and con-
trol), as well as different removal choices for both selection procedures.
As expected, averaged over 100 instances of the simulated experiment there was no signifi-
cant difference in the accuracy of the estimate of differential effects in the treatment group rela-
tive to the control group between the two sample size reduction methods. In both cases the
average accuracy was correct to within 1% with a statistically insignificant error from the
ground truth. However an examination of the corresponding estimate precisions readily reveals
a different picture. In particular across different experiment instances the proposed method
results in approximately 70% lower standard deviation of the target estimate; this is illustrated
in Fig 4. This finding illustrates with clarity the argument we put forward in the preceding sec-
tions. By performing sample selection in a manner which takes into account all available infor-
mation, the statistically best decision can be made about which specific samples can be
removed so as to ensure that in any particular case the associated information loss is mini-
mized. In the experiments which follow, we sought to examine in detail how different parame-
ters of a trial affect the precision improvement achieved with the proposed method.
Experiment 2: Effects of timing
As in the previous experiment, we used the data generation model from Experimental setup
and compared the proposed method with random sample selection in the context of a single
sample size reduction step. Our aim in this experiment was to investigate the effect that the
timing of participant removal, that is, the cessation of the corresponding data accrual, has on
the precision gained by using the proposed method. Hence we performed simulations for three
different time steps at which sample size reduction was performed, k = 30,50,70. All the other
parameters were kept constant—the number of participants removed was set to n = 50 (i.e.
approximately 28% of the total cohort size of 180), and the observability parameter which was
set to ϕ = 0.01. As before the final outcomes were analysed after kmax = 100 time steps using the
method described in [16], and for each combination of parameters 100 simulations were
performed.
Much like before and conforming to predictions from theory, we found no differential effect
between the average estimates produced by the proposed method and the naïve random
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selection-based approach—in both cases the average accuracy was correct to within 1% with a
statistically insignificant error from the ground truth. On the other hand the difference in pre-
cision was again stark and offered interesting insight into the proposed method. Our findings
are summarized by the plot in Fig 5 which shows the reduction in the standard deviation of the
estimate of the differential effect of treatment, across different simulation instances. Firstly,
observe that in all cases, that is, regardless of the time step at which sample size reduction was
performed, the proposed method achieved superior results over the naïve alternative. Secondly,
it is immediately apparent that the greatest benefit was found when sample size reduction was
performed earliest (i.e. after k = 30 time steps). In this case the standard deviation of the esti-
mate was reduced extensively, by approximately 39%. Lower but still substantial reduction of
approximately 16% was achieved when sample removal was performed half-way though the
duration of the simulated trials. When the removal was delayed to after 70% of the duration of
the trial, the standard deviation reduction was still significant at approximately 7%.
The observed behaviour of our algorithm is unsurprising and could be readily predicted
from theory.
Experiment 3: Effects of size adjustment
In this experiment our aim was to investigate the effect that the magnitude of sample size
reduction (i.e. the number of participants for whom data accrual is discontinued) has on the
precision gained by using the proposed method. The experiment was set up in the same man-
ner as Experiment 2 with the exception that now the time step at which sample size reduction
Fig 4. Estimates of the differential effect of treatment produced by the proposedmethod and the random selection-based baseline across 100
simulated trials. The estimates are shown ordered in magnitude for easier visualization. In all trial instances the reduction in the total number of participants
of n = 70 (i.e. approximately 39% of the total cohort size of 180) was performed after k = 50 time steps. Following the removal time step, data accrual from the
selected participants was discontinued but the data collected from them before that was still used in the final outcome analysis. Both the proposed method
and the random selection-based baseline exhibited no bias, with a statistically insignificant error and the accuracy of within 1% from the ground truth.
However the proposed method demonstrated far superior precision as readily observed from the plot; also see Figs 5–7.
doi:10.1371/journal.pone.0131524.g004
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was performed was set to k = 50 and kept at this value in all simulation instances, while the
number of participants who were removed from the continued accrual of data was treated as
an independent variable, n = 30, 50, 70. As before 100 simulations were performed with each
combination of parameters.
As in the previous experiments, the average accuracy of the estimate of the differential
effects of the treatment intervention over control was the same regardless of the sample selec-
tion strategy employed, but the corresponding precisions differed significantly. Our findings
are summarized by the plot in Fig 6. Again, it is worth starting with the most obvious observa-
tion, which is that in all cases the proposed methodology resulted in an improvement. The
greatest improvement was observed in the case when the sample size reduction was most dras-
tic, with the proposed algorithm achieving nearly 70% lower standard deviation than the ran-
dom selection-based alternative. This is of course consistent with our theoretical argument and
supportive of the propositions put forward in the preceding sections—the more the sample size
is reduced, the greater becomes the advantage of using all available information to make the
adjustment targeted to the specific cohort.
Experiment 4: Effects of perceptibility
In Belief refinement we highlighted the importance of ϕ, the observability parameter of the
model used to generate trial data. Recall that this parameter was introduced to model the ease
with which a participant can gauge the effects of the administered treatment i.e. the partici-
pant’s ability to observe an improvement or deterioration of the outcome of interest. The sig-
nificance that this inherent nature of the studied phenomenon has in the context of the
proposed sample size reduction methodology can be readily appreciated by observing that the
proposed approach derives key power from the stratification of patients based on their
responses to the auxiliary questionnaire (described in Auxiliary data collection). Consider the
Fig 5. The impact of sample size reduction timing on the precision of the estimate of the differential
effect of treatment. Plotted is the decrease in the standard deviation of the estimate across different
simulated trial instances (in %, relative to the random selection-based baseline). In all cases the proposed
method demonstrates a substantial improvement over the baseline. Greatest improvement is achieved for
early sample size adjustment. Also see Fig 4.
doi:10.1371/journal.pone.0131524.g005
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extreme case when perceptibility vanishes i.e. when ϕ = 0. In this case the collected auxiliary
data is effectively random and as such contributes no useful information to guide the selection
of participants which are to be removed from the trial. More generally, it can be said that the
lower the perceptibility of the outcome, the less there is to be gained from using the proposed
algorithm as compared to simple random selection.
Following the design adopted in the previous experiments, we performed 100 simulated tri-
als for each combination of parameter values, while keeping all of the trial variables fixed
except for the observability parameter. In addition to the previously used value of ϕ = 0.01, we
examined the performance benefit of using our algorithm when observability was halved (ϕ =
0.005) and doubled (ϕ = 0.02). In all cases the number of removed participants was set to
n = 50 which was performed after k = 50 time steps. The results are summarized in Fig 7 and
can be seen to match our theoretical expectations.
Experiment 5: Sequential adjustment
In the final experiment we report, we adopted a different experimental design than in the previ-
ous experiments. Specifically, in the previous experiments sample size reduction was under-
stood to result in the cessation of data accrual for the removed trial participants, but the data
accrued before their removal was still used in the final analysis of the trial outcomes. In con-
trast, in this experiment all data for the removed participants, including the data accrued before
removal, is discarded for the final analysis. This design captures those trial instances when the
studied treatment exhibits cumulative effects which complicate the analysis of outcomes
observed at different points in time.
Following the same practice as in the previous experiments, we used the data generation
model described in Experimental setup. However unlike before in this experiment sample size
Fig 6. The impact of sample size reduction magnitude on the precision of the estimate of the
differential effect of treatment. Plotted is the decrease in the standard deviation of the estimate across
different simulated trial instances (in %, relative to the random selection-based baseline). In all cases the
proposed method demonstrates a substantial improvement over the baseline. Greatest improvement is
achieved for the removal of a large number of participants. Also see Fig 4.
doi:10.1371/journal.pone.0131524.g006
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reduction was not performed at a single point in time. Rather a single participant was removed
after each time step. Clearly this is not intended to replicate any realistic scenario which could
be encountered in clinical practice. Though artificial in this sense, this experiment is useful as
an analytical tool in the study of the behaviour of the proposed algorithm.
It is insightful to start with a look at the impact that the removal of a part of the cohort has
on the estimate of the differential effect of the treatment intervention. A typical result is illus-
trated in Fig 8. This plot shows the posterior distributions of the differential effect of the treat-
ment inferred after the removal of 120 individuals obtained using the proposed method (red
line) and random selection (blue line). In both cases the posteriors were computed as described
in [16]. The most notable difference between the two distributions is in their spreads i.e. the
associated uncertainties. Specifically, the proposed method results in a much more peaked pos-
terior, that is, a much more confident estimate. In comparison, the posterior obtained using
random selection is much broader, admitting a lower degree of certainty associated with the
corresponding estimate.
The accuracy of the two methods is better assessed by observing their behaviour over time.
The plot in Fig 9 shows themaximum a posteriori estimates of the differential effect of treat-
ment obtained using the two methods during the course of the trial. Also shown is the ‘ground
truth’, that is, the actual differential effect which we can compute exactly from the setup of the
experiment (see Experimental setup). In the early stages of the trial, while the magnitude of the
accumulated effect is small and the number of participants large, the two estimates are virtually
indistinguishable, and they follow the ground truth plot closely. As expected, as the number of
participants removed increases both estimates start to exhibit greater stochastic perturbations.
However, both the accuracy (that is, the closeness to the ground truth) and the precision (that
is, the magnitude of stochastic variability) of the proposed method can be seen to show supe-
rior performance—itsmaximum a posteriori estimate follows the ground truth more closely
Fig 7. The impact of outcome perceptibility on the precision of the estimate of the differential effect of
treatment. Plotted is the decrease in the standard deviation of the estimate across different simulated trial
instances (in %, relative to the random selection-based baseline). In all cases the proposed method
demonstrates a substantial improvement over the baseline. Greatest improvement is achieved for trials with
high outcome perceptibility. Also see Fig 4.
doi:10.1371/journal.pone.0131524.g007
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Fig 8. Posterior distributions of the differential effect of treatment after the removal of 120 participants i.e. after 120 time steps; see Eqs (32)–(42).
The method introduced in this paper results in a much more certain estimate of the differential, as witnessed by the highly peaked distribution, than does
random selection.
doi:10.1371/journal.pone.0131524.g008
Fig 9. Themaximum a posteriori estimates of the differential effect of treatment during the course of the trial as an increasing number of
participants is removed. The blue line shows the estimates obtained using the proposed method, while the red line shows the estimates obtained using
random selection. Also shown is the ‘ground truth’ (green dotted line), that is, the actual differential effect computed exactly from the setup of the experiment
(see Experimental setup).
doi:10.1371/journal.pone.0131524.g009
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and fluctuates less than the estimate obtained when random selection is employed instead. It is
also important to observe the rapid degradation of performance of the random selection
method as the number of remaining participants becomes small, which is not seen in the pro-
posed method. This too can be expected from the theoretical argument put forward in Sub-
group selection—the statistically optimal choice of the sub-group from which participants are
removed ensures that the posterior is not highly dependent on a small number of samples
which would make it highly sensitive to the change in sample size.
Lastly, it is interesting to observe the differences between the changes in the sample sizes
within each sub-group using the two approaches. This is illustrated using the plots in Figs 10
and 11. As expected, when random participant removal is employed, the sizes of all sub-groups
decrease roughly linearly (save for stochastic variability), as shown in Fig 10. In contrast, the
sub-group size changes effected by the proposed method show more complex structure, gov-
erned by the specific values of the belief and effect variables in our experiment, as shown in Fig
11. It is particularly interesting to note that the size changes are not only non-linear, but also
non-monotonic. For example, the relative size of the control sub-group which includes individ-
uals which correctly identified their group assignment (i.e. the sub-group GC−) begins to
increase notably after the removal of 30 participants and starts to decrease only after the
removal of further 78 participants.
Summary and conclusions. In this paper we introduced a novel method for clinical trial
adaptation. Our focus was on adaptation by amending sample size. In contrast to all previous
work in this area, the problem we considered was not when sample size should be adjusted but
rather which particular individuals should be removed from the trial once the decision of sam-
ple reduction is made. Thus, our method is not an alternative to the current state-of-the-art,
Fig 10. The changes in the sample sizes within each of the six participant sub-groups (using the stratification described inMatching sub-groups
outcomemodel and adopted from [16]) observed in our experiment using random selection based participant removal.Note the predictable
outcome of the method, which results in a linear decrease of sample size for all sub-groups, and the contrasting behaviour of our approach in Fig 11.
doi:10.1371/journal.pone.0131524.g010
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but rather a complementary element of the same framework. Our approach is based on the
adopted stratification recently proposed for the analysis of trial outcomes in the presence of
imperfect blinding. This stratification is based on the trial participants’ responses to a generic
auxiliary questionnaire that allows each participant to express belief concerning his/her inter-
vention assignment (treatment or control). Extensive experiments on a simulated trial were
used to illustrate the effectiveness of our method.
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